David Durrant
Overview
Explore the profile of David Durrant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
724
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muccio P, Schueller J, Boas M, Howe N, Dabrowski E, Durrant D
Clin Med Insights Arthritis Musculoskelet Disord
. 2021 Mar;
14:1179544121993778.
PMID: 33746519
Chronic lower back pain is one of the most common medical conditions leading to a significant decrease in quality of life. This study retrospectively analyzed whether the AxioBionics Wearable Therapy...
2.
Nguyen K, Chau V, Mauro A, Durrant D, Toldo S, Abbate A, et al.
J Cardiovasc Pharmacol Ther
. 2020 May;
25(5):472-483.
PMID: 32390525
Aims: Hydrogen sulfide (HS) protects against ischemic and inflammatory injury following myocardial ischemia via induction of microRNA (miR)-21. We sought to determine whether HS attenuates ischemic heart failure with reduced...
3.
Samidurai A, Roh S, Prakash M, Durrant D, Salloum F, Kukreja R, et al.
Cardiovasc Res
. 2019 Nov;
116(13):2103-2115.
PMID: 31738412
Aims: Deregulation of mTOR (mammalian target of rapamycin) signalling occurs in diabetes, which exacerbates injury following myocardial infarction (MI). We therefore investigated the infarct-limiting effect of chronic treatment with rapamycin...
4.
Samidurai A, Salloum F, Durrant D, Chernova O, Kukreja R, Das A
Br J Pharmacol
. 2017 Oct;
174(24):4771-4784.
PMID: 28967097
Background And Purpose: Enhanced mammalian target of rapamycin (mTOR) signalling contributes to the pathogenesis of diabetes and plays a critical role in myocardial ischaemia/reperfusion (I/R) injury. Rapatar is a novel...
5.
Nagiub M, Filippone S, Durrant D, Das A, Kukreja R
Can J Physiol Pharmacol
. 2017 Feb;
95(3):295-304.
PMID: 28238269
The chemotherapeutic use of doxorubicin (Dox) is hindered due to the development of irreversible cardiotoxicity. Specifically, childhood cancer survivors are at greater risk of Dox-induced cardiovascular complications. Because of the...
6.
Das A, Durrant D, Mitchell C, Dent P, Batra S, Kukreja R
Oncotarget
. 2015 Dec;
7(4):4399-413.
PMID: 26716643
We previously reported that Sildenafil enhances apoptosis and antitumor efficacy of doxorubicin (DOX) while attenuating its cardiotoxic effect in prostate cancer. In the present study, we investigated the mechanism by...
7.
Das A, Durrant D, Salloum F, Xi L, Kukreja R
Pharmacol Ther
. 2014 Dec;
147:12-21.
PMID: 25444755
The phosphodiesterase 5 (PDE5) inhibitors, including sildenafil (Viagra™), vardenafil (Levitra™), and tadalafil (Cialis™) have been developed for treatment of erectile dysfunction. Moreover, sildenafil and tadalafil are used for the management...
8.
Toldo S, Das A, Mezzaroma E, Chau V, Marchetti C, Durrant D, et al.
Circ Cardiovasc Genet
. 2014 May;
7(3):311-20.
PMID: 24825878
Background: Maintaining physiological levels of hydrogen sulfide during ischemia is necessary to limit injury to the heart. Because of the anti-inflammatory effects of hydrogen sulfide, we proposed that the hydrogen...
9.
Das A, Durrant D, Koka S, Salloum F, Xi L, Kukreja R
J Biol Chem
. 2013 Dec;
289(7):4145-60.
PMID: 24371138
Elevated mammalian target of rapamycin (mTOR) signaling contributes to the pathogenesis of diabetes, with increased morbidity and mortality, mainly because of cardiovascular complications. Because mTOR inhibition with rapamycin protects against...
10.
Das A, Salloum F, Durrant D, Ockaili R, Kukreja R
J Mol Cell Cardiol
. 2012 Sep;
53(6):858-69.
PMID: 22999860
Rapamycin (Sirolimus®) is used to prevent rejection of transplanted organs and coronary restenosis. We reported that rapamycin induced cardioprotection against ischemia-reperfusion (I/R) injury through opening of mitochondrial K(ATP) channels. However,...